Clinical trials: Cardiovascular Disease Acute
Acute Myocardial Infarction
SpinChip Hs-cTnI Determination of the 99th Percentile URL
During a heart attack, the protein troponin I is released from the heart muscle into the bloodstream. Measurements of cardiac troponin in blood are used as an aid in the diagnosis of heart attack.
- Trial name
- HEAT-3 (NCT06463275)
- Testing
- SpinChip hs-cTnI
- Where
- 4 sites in Sweden
- Volunteers
- 1,355 people, healthy volunteers welcome
- Sponsor
- SpinChip Diagnostics ASA
Acute Ischemic Stroke
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.
- Trial name
- RAISE (NCT06226805)
- Testing
- BB-031
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 228 people
- Sponsor
- Basking Biosciences, Inc.
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndromes
An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index…
- Trial name
- TARGET (NCT01061086)
- Where
- 11 sites in Greece
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke
- Trial name
- iNFLOW-5 (NCT07571954)
- Testing
- Thromboaspiration catheter
- Where
- 7 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- iVascular S.L.U.
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
- Trial name
- NCT00856661
- Testing
- Desmoteplase
- Where
- 152 sites in United States, Belgium and 12 more
- Volunteers
- 270 people
- Sponsor
- H. Lundbeck A/S
Aneurysm, Dissecting, Aortic Aneurysm
Study of the Influence of the Moon and Seasons On Outcomes Following Surgery To Repair Ascending Aortic Dissection
That the full-moon stage of the lunar cycle is associated with reduced mortality and shorter length of stay in patients undergoing repair of aortic dissection, after adjusting for seasonal effects, demographics and cardiovascular…
- Trial name
- ACS-MOON-1 (NCT02236923)
- Where
- United Kingdom
- Volunteers
- 2,684 people
- Sponsor
- 22EON
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Stroke, Acute
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.
- Trial name
- NCT00123305
- Testing
- Microplasmin
- Where
- 16 sites in Austria, Belgium and 1 more
- Volunteers
- 40 people
- Sponsor
- ThromboGenics
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3-9 hours from onset of stroke symptoms.
- Trial name
- DIAS-3 (NCT00790920)
- Testing
- Desmoteplase
- Where
- 102 sites in Australia, Austria and 15 more
- Volunteers
- 492 people
- Sponsor
- H. Lundbeck A/S
AIS, Acute Ischemic Stroke
A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel occlusion in the cerebral circulation.
- Conditions
- AIS, Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy
- Trial name
- NCT05496361
- Testing
- Tianyi Revascularization Device, Solitaire FR Revascularization Device
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Dyspnea, Hypertension
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
The purpose of this study is to evaluate dyspnea improvement and other parameters of efficacy and safety in acute heart failure (AHF) patients receiving an intravenous (IV) infusion of clevidipine in comparison to standard of…
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Trial name
- PRONTO II (NCT04592380)
- Testing
- Stage 1: Clevidipine (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Where
- 9 sites in United States
- Sponsor
- The Medicines Company
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory…
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05020678
- Testing
- NKX019
- Where
- 6 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Nkarta, Inc.
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Acute Stroke
Efficacy of EMF BCI Based Device on Acute Stroke
The study tests the efficacy of a non-invasive device with low intensity electromagnetic field dedicated treatment to enhance the recovery of stroke patients impaired hand motor function
- Trial name
- NCT04039178
- Testing
- BQ
- Where
- India
- Volunteers
- 28 people
- Sponsor
- BrainQ Technologies Ltd.
Acute Cerebral Ischemia
Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.
- Trial name
- NCT05955326
- Testing
- Sovateltide, Normal Saline
- Where
- 6 sites in India
- Volunteers
- 160 people
- Sponsor
- Pharmazz, Inc.
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company
Hereditary Angioedema (HAE)
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE).
- Trial name
- NCT03240133
- Testing
- BCX7353
- Where
- 24 sites in Austria, Denmark and 10 more
- Volunteers
- 58 people
- Sponsor
- BioCryst Pharmaceuticals
Stroke
Evaluation of Improvement in Mobility Skills for Sub-acute Stroke Patients, Using the Selfit System.
Stroke is a leading cause of mobility disability for adults. Selfit is an advanced practice system that enables a wide range of exercises to improve patient mobility in the sub-acute stage after a stroke.
- Trial name
- Selfit (NCT03671876)
- Testing
- Intervention plus therapy
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Selfit Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.